Drug insight: Statins for nonischemic heart failure - Evidence and potential mechanisms

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 4, 2007, Pages 196-205

  Lipinski, Michael J ^a   Abbate, Antonio ^a   Fuster, Valentin ^c   Vetrovec, George W ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Marie Josee and Henry R Kravis Center for Cardiovascular Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; ENDOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOSARTAN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

ANTIINFLAMMATORY ACTIVITY; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; SYSTEMATIC REVIEW; THROMBOSIS;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE, CONGESTIVE; HEART FUNCTION TESTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33947660903     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0855     Document Type: Review

References (83)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
2. Sever PS et al.; ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361: 1149-1158
3. Jain MK and Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-987
4. Robinson JG et al. (2005) Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46: 1855-1862
5. Kjekshus J et al. (1997) The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3: 249-254
6. Aronow WS and Ahn C (2002) Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 90: 147-149
7. Scirica BM et al.; PROVE IT-TIMI 22 Investigators (2006) Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47: 2326-2331
8. Sakamoto T et al.; Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction Investigators (2006) Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97: 1165-1171
9. Khush KK et al. (2007) Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) Study. Circulation 115:576-583
10. Hognestad A et al.; OPTIMAAL Investigators (2004) Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 93:603-606
11. Lipinski MJ et al. (2006) Effect of statins and white blood cell count on mortality in patients with ischemic left ventricular dysfunction undergoing percutaneous coronary intervention. Clin Cardiol 29: 36-41
12. Horwich TB et al. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43: 642-648
13. Folkeringa RJ et al. (2006) Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 12: 134-138
14. Foody JM et al. (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113: 1086-1092
15. Go AS et al. (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296: 2105-2111
16. Anker SD et al. (2006) Statin use and survival in patients with chronic heart failure-results from two observational studies with 5,200 patients. Int J Cardiol 112: 234-242
17. Ray JG et al. (2005) Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165: 62-67
18. Sola S et al. (2005) Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 11: 607-612
19. Hedrich O et al. (2004) Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coron Artery Dis 15: 291-297
20. Horwich TB et al. (2002) Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8: 216-224
21. Rauchhaus M et al. (2000) The endotoxin-lipoprotein hypothesis. Lancet 356: 930-933
22. Christ M et al. (2006) Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 27: 691-699
23. Batin P et al. (1995) The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 16: 1613-1618
24. May HT et al. (2006) Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol 98: 653-658
25. Heart Protection Study Collaborative Group; Emberson JR et al. (2007) N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49: 311-319
26. Jernberg T et al. (2004) Natriuretic peptides in unstable coronary artery disease. Eur Heart J 25: 1486-1493
27. Maisel AS et al.; Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167
28. Rauchova H et al. (1995) Function of coenzyme Q in the cell: Some biochemical and physiological properties. Physiol Res 44: 209-216
29. Soja AM and Mortensen SA (1997) Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 18 (Suppl): S159-S168
30. Watts GF et al. (1993) Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 46: 1055-1057
31. Folkers K et al. (1990) Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 87: 8931-8934
32. Bleske BE et al. (2001) The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 142: E2
33. Berthold HK et al. (2006) Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: A randomised trial. Drug Saf 29: 703-712
34. Strey CH et al. (2005) Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179: 201-206
35. Sander S et al. (2006) The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12: 464-472
36. Kinlay S et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators (2003) High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108: 1560-1566
37. Chan AW et al. (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105: 691-696
38. Ridker PM et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965
39. Stewart RA et al.; Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Investigators (2005) White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation 111: 1756-1762
40. Tousoulis D et al. (2005) Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178: 359-363
41. Sola S et al. (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47: 332-337
42. Mozaffarian D et al. (2005) The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 96: 1699-1704
43. Ferns GA (2003) Differential effects of statins on serum CRP levels: implications of recent clinical trials. Atherosclerosis 169: 349-351
44. Hackam DG et al (2006) Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 367: 413-418
45. Liappis AP et al. (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33: 1352-1357
46. Niessner A et al. (2006) Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 189: 408-413
47. Majumdar SR et al. (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 333: 999
48. Mathier MA et al. (1998) Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 32: 216-224
49. Ross R (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809
50. John S et al. (2005) Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 149: E473
51. Beckman JA et al. (2004) Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 95: 217-223
52. Landmesser U et al. (2005) Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111: 2356-2363
53. Tousoulis D et al. (2005) Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7: 1126-1132
54. Bleske BE et al. (2006) Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47: 338-341
55. Loscalzo J (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88: 756-762
56. Fuster V et al. (1981) The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47: 525-531
57. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) (2005) ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46: 1116-1143
58. Casani L et al. (2005) Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 94: 1035-1041
59. Schafer A et al. (2005) Rosuvastatin reduces platelet activation in heart failure: Role of NO bioavailability. Arterioscler Thromb Vasc Biol 25: 1071-1077
60. Tousoulis D et al. (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91: 27-31
61. Su SF et al. (2000) Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 86: 514-518
62. Node K et al. (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843
63. Ohara Y et al. (2005) Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty. Int Heart J 46: 987-995
64. Tiefenbacher CP et al. (2004) ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 286: H1425-H1432
65. Bates K et al. (2002) Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 283: H768-H775
66. Fuller SJ et al. (1998) Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem 273: 18146-18152
67. Nakagami H et al. (2003) A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 35: 398-403
68. Cleland JG et al. (2006) Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail 8:326-329
69. Nolan J et al. (1998) Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98: 1510-1516
70. Pliquett RU et al. (2003) Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107: 2493-2498
71. Hamaad A et al. (2005) Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 19: 183-187
72. Lipinski MJ et al. (2005) The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction. J Cardiac Fail 11: 624-630
73. Katircibasi MT et al. (2005) Decreased heart rate recovery in patients with heart failure: Effect of fluvastatin therapy. Int Heart J 46: 845-854
74. Pliquett RU et al. (2003) Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95: 700-704
75. Ito M et al. (2004) Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110: 412-418
76. Krum H et al. (2006) Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II. Cardiology 108: 28-34
77. Nickenig G et al. (1999) Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100: 2131-2134
78. Maack C et al. (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1 -GTPase and represents a target for statin treatment. Circulation 108: 1567-1574
79. Saijonmaa O et al. (2004) Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 286: H2096-H2102
80. van der Harst P et al. (2005) Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am J Cardiol 96: 1361-1364
81. Horiuchi M et al. (2003) Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107: 106-112
82. Kjekshus J et al. (2005) A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7: 1059-1069
83. Tavazzi L et al. (2004) Rationale and design of the GISSI heart failure trial: A large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6: 635-641